LF
LFTSF.US LifeTech Scientific Corporation
- Market cap
- USD 880M
- P/E
- -
- P/B
- 1.77x
- ROE
- -4.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is LFTSF.US undervalued?
Graham numberThe Graham number of LifeTech Scientific Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LifeTech Scientific Corporation fundamental analysis
No fundamental analysis for LifeTech Scientific Corporation yet.
LifeTech Scientific Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. It is also involved in biomedical…
Full company profileLifeTech Scientific Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LifeTech Scientific Corporation annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 353M | 409M | 557M | 669M | 642M | 925M | 1.10B | 1.27B | 1.30B | 1.37B | 2.40B |
| Gross Profit | 277M | 332M | 455M | 535M | 513M | 748M | 874M | 996M | 981M | 1.02B | 1.86B |
| Operating Income | 108M | 192M | 164M | 189M | 264M | 329M | 376M | 383M | 186M | 176M | -45.0M |
| EBITDA | 120M | 211M | 200M | 246M | 331M | 398M | 446M | 253M | 289M | 295M | 287M |
| Net Income | 146M | 163M | 121M | 129M | 216M | 292M | 325M | 263M | 222M | 148M | -137M |
| EPS | 0.04 | 0.04 | 0.03 | 0.03 | 0.05 | 0.06 | 0.07 | 0.06 | 0.05 | 0.03 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 1.33B | 1.27B | 1.53B | 1.77B | 2.95B | 3.18B | 3.69B | 4.70B | 4.90B | 5.01B | 4.75B |
| Total Liabilities | 459M | 214M | 287M | 611M | 596M | 654M | 769M | 1.37B | 1.42B | 1.54B | 1.48B |
| Shareholders' Equity | 868M | 1.05B | 1.24B | 1.15B | 2.34B | 2.50B | 2.90B | 3.37B | 3.49B | 3.51B | 3.32B |
| Cash & Short-term Investments | 645M | 452M | 358M | 349M | 1.14B | 1.48B | 834M | 1.18B | 1.18B | 1.15B | 1.24B |
| Total Debt | 200M | - | 24.0M | 353M | 186M | 15.7M | 9.67M | 9.30M | 4.98M | 8.04M | 14.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 127M | 155M | 182M | 275M | 339M | 489M | 388M | 418M | 321M | 549M | 1.42B |
| Capital Expenditure | 108M | 153M | 112M | 159M | 158M | 343M | 335M | 293M | 283M | 150M | 71.7M |
| Free Cash Flow | 19.0M | 1.95M | 70.2M | 116M | 180M | 146M | 52.8M | 125M | 38.5M | 399M | 1.35B |
| Ratios | |||||||||||
| ROE | 16.8% | 15.5% | 9.8% | 11.2% | 9.2% | 11.7% | 11.2% | 7.8% | 6.4% | 4.2% | -4.1% |
| ROA | 11.0% | 12.9% | 7.9% | 7.3% | 7.3% | 9.2% | 8.8% | 5.6% | 4.5% | 2.9% | -2.9% |
| Net Profit Margin | 41.3% | 40.0% | 21.8% | 19.3% | 33.6% | 31.6% | 29.6% | 20.8% | 17.1% | 10.8% | -5.7% |
| Debt to Equity | 0.23x | - | 0.02x | 0.31x | 0.08x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
LifeTech Scientific Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 280M | 0.07 | 216.7% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LifeTech Scientific Corporation
- Insiders 22.45%
- Institutions 7.47%
- Public & others 70.08%
- Shares outstanding 4.40B
- Free float 3.58B
LifeTech Scientific Corporation company profile
- Company name
- LifeTech Scientific Corporation
- Ticker
- LFTSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,254
- Fiscal year end
- December
- Address
- LifeTech Scientific Building, Shenzhen, China, 518063
- Phone
- 86 75 5860 26250
- Website
- lifetechmed.com
About LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. It is also involved in biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.
LifeTech Scientific Corporation management
5- Mr. Yuehui XieFounder, Executive Chairman & CEO · born 1969
- Mr. Jianxiong Liu ACCACFO, Executive VP & Company Secretary · born 1971
- Ms. Xingmei RuanChief Compliance Officer · born 1984
- Ms. Liping WuExecutive Director · born 1981
- Mr. Yu FangExecutive Director · born 1979